Its September 2026 investor presentation highlights clinical progress for aglatimagene besadenovec and linoserpaturev, two programs designed to support cancer treatment development.
The event gives investors access to a live webcast through the company’s investor website as Cardiol (NASDAQ: CRDL) advances therapies for inflammatory and fibrotic heart disease.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) President and CEO Barber Daniel recorded a code X transaction involving 91,743 shares at $0.96 per share on September 8, 2026. His resultingEquityposition stood at 677,317 shares. Barber’s resulting derivative securities position was 0.
The changes became effective on September 2 afterShareholderapproval on August 25 and registration confirmation from the Cayman Islands Registrar of Companies on September 7.
RoyaLand Co Ltd. (OTC: RLNDF) is advancing Savoia 1908 FC’s professional-football project with a squad valued at approximately €3.88 million and a stated objective of securing its position in Serie C. The BermudaHolding Companysays the club’s longer-term strategy is to develop young players, build …
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) shares were sold by Chief Operating Officer Neervannan Seshadri at $85 per share, with 4,564 shares changing hands.
TAT TECHNOLOGIES LTD (NASDAQ: TATT) received approval for every proposal presented at its 2026 annual general meeting, with approximately 72% of its outstanding ordinary shares represented and voted. The meeting outcome covers the proposals included in the company’s proxy materials.
Where Food Comes, Inc. (NASDAQ: WFCF) determined that its disclosure controls were ineffective as of December 31, 2025, after identifying a material weakness in lease accounting. Management said the weakness involved the improper application of FASB ASC 842 and resulted in material overstatements of …
Wing Yip Food Holdings Group Ltd (NASDAQ: WYHG) awarded Chief Executive Officer Wang Tingfeng 13,000,000 shares. The transaction was recorded on 7 September 2026.
Adagene Inc. (NASDAQ: ADAG) reached a preclinical milestone for XB404 in its collaboration with Exelixis, generating a $2.0 million payment. The SAFEbody-built antibody-drug conjugate candidate is designed to target tumors expressing ROR1/2 while limiting effects on healthy tissue.